Skip to content

Randomized controlled clinical trial of Dan Zhi Jiang Tang Capsule in treating type 2 diabetes mellitus with Qi Yin deficiency and blood stasis syndrome

Randomized controlled clinical trial of Dan Zhi Jiang Tang Capsule in treating type 2 diabetes mellitus with Qi Yin deficiency and blood stasis syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049613
Enrollment
Unknown
Registered
2021-08-06
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Sponsors

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years (including both ends), gender is not limited; 2. Patients with type 2 diabetes who meet the diagnostic criteria of Western medicine for diabetes; 3. Those who conform to the syndrome of qi and yin deficiency in traditional Chinese medicine with blood stasis; 4. Those who only received metformin hydrochloride tablets, and 0.5g/time, 3 times/day, not less than 2 weeks; 5. Poor control: blood sugar [6.5mmol/L<=FPG (venous blood)<=10.0mmol/L; 7.0%<HbA1c (glycated hemoglobin)<=9.0%]; 6. Patients were informed and signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with type 2 diabetes who need insulin therapy; 2. Patients with acute complications of diabetes; 3. Combined with severe cardiovascular and cerebrovascular diseases and serious primary diseases such as liver, kidney and hematopoietic system; 4. Those who are allergic to the known ingredients of the research drug and have allergic constitution; 5. Pregnant, lactating patients and those who have a childbearing plan in the near future; 6. Long-term alcoholism, drug dependence, mental illness patients; 7. Patients who have taken oral Chinese medicine or Chinese patent medicine for hypoglycemic purpose within 1 month before screening; 8. Those who have participated in or are participating in other drug clinical trials within one month before the screening period of this study; 9. The researcher believes that it is not suitable to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose;2h postprandial venous blood glucose;

Countries

China

Contacts

Public ContactZhao Jindong

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

zhaojindong1111@163.com+86 15256571336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026